DingMd, PhdWangMD

Oncology • Detroit, MI

Gynecologic Cancer, Melanoma, Neuro-Oncology

Phase 1 Clinical Trials & Rare Cancer Therapeutics Program Director

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
2799 West Grand Boulevard
Henry Ford Cancer Institude
Detroit, MI 48202
Phone+1 313-916-2600

Fax+1 313-916-7911

Education & Training

Henry Ford Health/Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1997 - 2000
Beijing Medical UniversityClass of 1983

Certifications & Licensure

MI State Medical License 2002 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
Completed
Phase 2
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Start of enrollment: 2011 Apr 01
Completed
Phase 1
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Start of enrollment: 2017 Feb 08
Terminated
Phase 1, Phase 2
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer Start of enrollment: 2017 Dec 01
Completed
Phase 1
Study of LM-102 in Subjects in Advanced Tumors Start of enrollment: 2021 May 27
Terminated
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

233 citations
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-la...
James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler
The Lancet. Oncology. 2017-05-01
458 citations
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang
Journal of Clinical Oncology. 2017-04-04
243 citations
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Susan M. Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean Pierre Delord
The Lancet. Oncology. 2020-09-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member